Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.53 |
| ▸ | PRKDC | P78527 | 14/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | XRCC6 | P12956 | 1/20 | 0.49 |
| ▸ | XRCC5 | P13010 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.49 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.49 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449184 | 0.89 | PRKDC (0.58) | PIK3CAPIK3CDPIK3CGPRKDCPIK3CB | |
| SCHEMBL13276510 | 0.88 | PIK3CB (0.58) | PIK3CAPIK3CDPIK3CGPIK3CBMTOR | |
| SCHEMBL1638322 | 0.86 | PRKDC (0.55) | PIK3CAPIK3CDPIK3CGPRKDCPIK3CB | |
| SCHEMBL1637213 | 0.86 | PIK3CB (0.63) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12666453 | 0.85 | PRKDC (0.52) | PIK3CAPIK3CDPIK3CGPRKDCPIK3CB | |
| SCHEMBL1636575 | 0.84 | PRKDC (0.57) | PIK3CAPIK3CDPIK3CGPRKDCPIK3CB | |
| SCHEMBL24713569 | 0.82 | PRKDC (0.52) | PIK3CAPIK3CDPIK3CGPRKDCPIK3CB | |
| SCHEMBL28946196 | 0.82 | PIK3CA (0.50) | PIK3CAPIK3CDPIK3CGPRKDCPIK3CB | |
| SCHEMBL1639079 | 0.81 | PIK3CB (0.60) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL1865332 | 0.81 | PIK3CB (0.53) | PIK3CAPIK3CDPIK3CGPRKDCPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4284375-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022164812-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022164812-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| WO-2012140419-A1 | CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | WO | disclosed |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| CN-102712615-A | Chromenone Derivatives with Antitumor Activity | ASTRAZENECA AB | 2012-10-03 | — | — | CN | disclosed |
| EP-2493870-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098271-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CA 2099/4885PIK3CD 3037/4885PIK3CG 3778/4885 |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CA 2099/4885PIK3CD 3037/4885PIK3CG 3778/4885 |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND1 | PIK3CA 1609/4885PIK3CD 2843/4885PIK3CG 3487/4885 |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CB, PI4KA | PIK3CA 1/4885PIK3CD 4/4885PIK3CG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.